Enhancement of Proteasomal Function Protects Against Cardiac Proteinopathy and Ischemia/Reperfusion Injury in Mice

Jie Li¹, Kathleen M. Horak¹, Huabo Su¹, Atsushi Sanbe², Jeffrey Robbins², Xuejun Wang¹

¹Division of Basic Biomedical Sciences (J.L., K.M.H., X.W.), Sanford School of Medicine of the University of South Dakota, Vermillion, SD, USA; ²The Heart Institute (A.S., J.R.), Cincinnati Children's Hospital Medical Center, Cincinnati, OH, USA

Online Supplementary Data

Supplementary Figures and Legends





Figure S2. Effects of $PA28\alpha OE$ on the size distribution of proteasome complexes in mouse myocardium.

A, gel filtration and subsequent western blot analyses of myocardial native protein extracts. RPN2, PSMB5, and PA28 β were immunoblotted to respectively probe 19S, 20S, and 11S subcomplexes in different elution fractions. The fraction numbers are indicated at the top of the image. The positions of molecular weight markers (arrowheads at the top) were determined by using the high molecular weight calibration standards to run through the column separately but under the same conditions. The estimated positions of the indicated proteasome complexes are shown at the bottom. **B**, immunoprecipitation (IP) of 20S proteasomes to detect associated 19S and 11S proteasomes. Crude protein extracts from myocardium of tTA single transgenic (CTL) or PA28 α /tTA double transgenic (OE) mice were used for IP with either an affinity purified rabbit Ig G antibody specifically against the α 3 subunit of 20S proteasomes (donated by Dr. Peipei Ping of UCLA) or rabbit IgG control. The IP products were fractionated by 12% SDS-PAGE, transferred to PVDF membranes, and subjected to immunoblot for 20S α 4 subunit, PA28α, and Rpt6 (a constitutive subunit of 19S proteasome). C and D, western blot images (C) and densitometry data (D) of the protein levels of RPN2 and RPT6 of the 19S and the core subunits of 20S along with PA28a in ventricular myocardium. 19S and 20S subunit protein levels were not changed by PA28 α OE. Mean+SD; *: p<0.001, PA28 α /tTA double TG vs. tTA single TG; n=3, Student's t-test.







Figure S5. Confocal micrographs of double immunofluorescence staining for CryAB (green) and α -actinin (red) in ventricular myocardium obtained from mice of the indicated genotypes. Note that CryAB positive protein aggregates are only detectable in CryAB^{R120G} transgenic hearts. TG, transgenic; DTG, double TG; Scale bar = 20 μ m

	LVIDd	LVPWd	LVIDs	LVPWs	LVAWd	LVAWs	LVVd	LVVs	%EF	% FS	HR
2 month NTG (n=10)	3.65 ± 0.34	0.81 ± 0.11	2.34 ± 0.35	1.24 ± 0.25	0.62 ± 0.07	1.09 ± 0.14	62.9 ± 11.8	22.2 ± 6.4	54.0 ± 11.8	38.2 ± 5.3	456 ± 34
α -/tTA+ (n=9)	3.64 ± 0.26	0.72 ± 0.11	2.35 ± 0.28	1.19 ± 0.15	0.66 ± 0.09	1.06 ± 0.09	57.9 ± 8.6	20.3 ± 6.5	56.3 ± 12.6	39.7 ± 2.9	482 ± 53
α +/tTA- (n=12)	3.64 ± 0.26	0.74 ± 0.115	2.32 ± 0.33	1.11 ± 0.17	0.65 ± 0.09	1.10 ± 0.10	57.0 ± 8.6	21.1 ± 3.9	52.1 ± 14.2	39.5 ± 6.1	465 ± 43
α +/tTA+ (n=11)	3.71 ± 0.3	0.80 ± 0.12	2.36 ± 0.35	1.25 ± 0.20	0.67 ± 0.10	1.16 ± 0.20	63.2 ± 10.1	21.4 ± 3.0	56.9 ± 12.0	41.5 ± 6.5	477 ± 22
8 month											
NTG (n=9)	3.88 ± 0.11	0.86 ± 0.15	2.43 ± 0.22	1.31 ± 0.12	0.85 ± 0.18	1.24 ± 0.16	65.2 ± 4.2	23.5 ± 4.6	64.2 ± 4.9	34.6 ± 5	512 ± 30
α -/tTA+ (n=11)	3.78 ± 0.34	0.86 ± 0.10	2.58 ± 0.42	1.24 ± 0.25	0.81 ± 0.12	1.21 ± 0.18	61.8 ± 12.5	25.1 ± 8.5	60.6 ± 8.3	32.1 ± 6.1	502 ± 31
α+/tTA- (n=9)	3.86 ± 0.19	0.89 ± 0.06	2.49 ± 0.16	1.34 ± 0.11	0.87 ± 0.12	1.30 ± 0.17	64.6 ± 7.4	22.2 ± 3.4	65.5 ± 3.8	35.5 ± 3.8	491 ± 45
α +/tTA+ (n=11)	3.80 ± 0.26	0.86 ± 0.17	2.50 ± 0.28	1.24 ± 0.24	0.85 ± 0.14	1.20 ± 0.15	62.5 ± 10.1	25.5 ± 4.0	62.5 ± 6.8	33.4 ± 4.9	474 ± 37
12 month											
NTG (n=9)	3.97 ± 0.19	0.89 ± 0.23	2.77 ± 0.3	1.32 ± 0.25	0.84 ± 0.20	1.19 ± 0.21	68.9 ± 7.9	29.3 ± 6.1	57.7 ± 7.7	30.3 ± 5	482 ± 19
α -/tTA+ (n=10)	3.83 ± 0.17	0.93 ± 0.18	2.57 ± 0.19	1.27 ± 0.21	0.82 ± 0.11	1.19 ± 0.18	63.2 ± 6.7	24.0 ± 4.5	60.7 ± 5.1	33.0 ± 3.4	493 ± 19
α+/tTA- (n=11)	3.96 ± 0.34	0.92 ± 0.14	2.79 ± 0.35	1.28 ± 0.16	0.88 ± 0.14	1.26 ± 0.17	69.3 ± 13.4	29.9 ± 9.1	57.4 ± 7.2	29.9 ± 4.7	496 ± 34
α +/tTA+ (n=13)	3.92 ± 0.20	0.86 ± 0.09	2.76 ± 0.18	1.17 ± 0.14	0.82 ± 0.11	1.14 ± 0.12	67.8 ± 9.2	28.3 ± 4.2	57.2 ± 4.2	30.2 ± 2.3	495 ± 17

Supplementary Table 1. Serial Echocardiographic analysis of mice

 α -/tTA+: PA28 α NTG/tTA TG; α +/tTA-: PA28 α TG/tTA NTG; α +/tTA+: PA28 α TG/tTA TG; n: number of animals; LVIDd : Diastolic Left Ventricle Interdiameter; LVIDs: Systolic Left Ventricle Interdiameter; LVPWd: Diastolic Left Ventricle Posterior Wall; LVPWs: Systolic Left Ventricle Posterior Wall; LVAWd: Diastolic Left Ventricle Anterior Wall; LVAWs: Systolic Left Ventricle Anterior Wall; LVVd: Diastolic Left Ventricle Volume; LVVs: Systolic Left Ventricle Volume; EF: Ejection Fraction; FS: Fractional Shortening; HR: Heart Rate; Mean ±SD, One way ANOVA. No significant difference observed between groups at any time point.

	BW(g)	HW(mg)	HW/BW (mg/g)	VW/BW (mg/g)	LvW/BW (mg/g)	RvW/BW (mg/g)	LW/BW (mg/g)	LiW/BW (mg/g)	KW/BW (mg/g)	HW/TL (mg/g)
Ntg(n=6)	36.1 ± 6.0	135.7 ± 24.5	3.9 ± 0.2	3.4 ± 0.2	$2.6\ \pm 0.1$	0.8 ± 0.1	4.8 ± 0.8	39.7 ± 5.4	11.3 ± 0.8	7.3 ± 0.8
a-/tTA+(n=8)	33.5 ± 4.7	141.1 ± 17.0	4.3 ± 0.5	3.9 ± 0.5	3.0 ± 0.4	0.8 ± 0.1	4.4 ± 0.5	43.3 ± 4.3	12.1 ± 1.5	7.7 ± 0.6
a+/tTA-(n=7)	36.4 ± 4.2	143.1 ± 15.1	3.9 ± 0.2	3.5 ± 0.1	2.8 ± 0.2	0.8 ± 0.1	4.4 ± 0.5	43.3 ± 4.3	12.1 ± 1.5	7.7 ± 1.5
a+/tTA+(n=11)	36.3 ± 5.3	148.8 ± 20.5	4.1 ± 0.5	3.7 ± 0.4	2.8 ± 0.3	0.8 ± 0.1	4.7 ± 0.6	44.1 ± 3.9	11.9 ± 2.1	7.9 ± 1.1

Supplementary Table 2. Gravimetric measurements of 1-year old mice

α-/tTA+: PA28α NTG/tTA TG; α+/tTA-: PA28α TG/tTA NTG; α+/tTA+: PA28α TG/tTA TG; BW: Body Weight; HW: Heart Weight; VW: Ventricle Weight; TL: Tibia Length; LvW: Left ventricle Weight; RvW: Right ventricle Weight; LW: Lung Weight; LiW: Liver Weight; KW: kidney Weight; mean ±SD, One way ANOVA; no significant difference observed between groups.

	tTA	tTA/mCryAB	PA28a/tTA/mCryAB		
	n=7	n=13	n=13		
BW (g)	27.98±2.92	30.56±4.26	27.34±4.40		
HR (bpm)	474±44	449±34	479±50		
LVID;d (mm)	3.73±0.2	3.89±0.39	3.72±0.25		
LVPW;d (mm)	0.85 ± 0.14	1.05±0.17*	0.90±0.09†		
LVID;s (mm)	2.56±0.25	2.46±0.41	2.24±0.37		
LVPW;s (mm)	1.17±0.17	1.53±0.21**	1.42±0.13*		
LVAW;d (mm)	0.78 ± 0.07	0.97±0.10**	0.85±0.09†		
LVAW;s (mm)	1.12±0.12	1.51±0.14**	1.39±0.12**†		
LV %EF	59.83±7.66	66.69±9.03	70.74±8.84*		
LV % FS	31.49±5.53	36.85±7.32	40.01±7.53*		
LV Mass (mg)	86±16	124±19**	95±16††		

Supplementary Table 3. Echocardiographic Findings at 12 Weeks of Age

* P< 0.05 vs tTA; ** P< 0.001 vs tTA; † P<0.05 vs tTA/mCryAB; †† P<0.001 vs tTA/mCryAB; one way ANOVA and Holm-Sidak test.